PREDICTIVE CANCER THERAPY EFFICACY MODELLING
Versatile and flexible research technologies and platforms allowing HT and HC screens for identification of clinically relevant drug sensitivity in ex vivo patient derived cell cultures from rare and aggressive solid cancer samples. Imaging based drug screening using pathology informed cell type biomarkers.
Therapy efficacy and resistance testing using a small number of cells isolated from coarse needle biopsy, ascites/pleural fluid or tumor sample. Rapid assay turnaround time of 3-5 days. Cell response phenotyping using multi-parameter image-based cytometry for single cell resolution results. Results comparison with Misvik Cancer Cell Line Panel and data from public databases.
State-of-the-art microcope instrumentation, image cytometry, flow cytometry versatile panels of surrogate imaging assays for cancer cell hallmark phenotypes, screening libraries covering all FDA & EMA approved therapeutics, diverse natural product and discovery chemical small molecule collections.